LEEDS, United Kingdom – The parents of a five-month-old girl with cystic fibrosis fear that their daughter could lose access to a life-changing drug, which they say would be like living with a “death sentence.” Layla has been in and out of the hospital since being diagnosed with the inherited condition, and her parents are hoping that she would be given access to Kaftrio, a drug that significantly improves lung function and overall quality of life for cystic fibrosis patients.
The National Institute for Health and Care Excellence (NICE) has published draft guidance deeming the drug too expensive to be offered on the NHS, sparking fears that Layla and other patients may lose access to the medication in the future. The drug costs £200,000 per year for each patient, leading to concerns that NHS funding for the drug may be withdrawn.
The situation has left Layla’s parents struggling with anxiety, as the fear of their daughter not being able to access the drug when she turns two feels like a “death sentence.” They express disbelief and dismay at the idea of putting a value on a child’s life and are pushing for continued access to the drug for their daughter and others in similar situations.
Other families affected by cystic fibrosis have also voiced their support for the drug, emphasizing the significant positive impact it has had on their loved ones’ lives. The promising results of the drug have led to calls for NICE to continue to prescribe Kaftrio, as it has transformed the lives of patients who had previously been struggling with the condition.
NICE has stated that it is still in the process of determining the most appropriate next steps and will provide an update later this month. It has also assured that access to treatments will continue for those already taking the drug and for new patients, at least until the ongoing appraisal is completed. This situation has placed a spotlight on the healthcare system’s approach to expensive but life-changing medications and the impact such decisions have on patients and their families.